{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:50:49Z","timestamp":1794412249143,"version":"4.9.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82220108003"],"award-info":[{"award-number":["82220108003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.gendis.2025.101913","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:52:47Z","timestamp":1761947567000},"page":"101913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dendritic cell vaccines: Current research progress, challenges, and opportunities"],"prefix":"10.1016","volume":"13","author":[{"given":"Shilin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenxia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhen","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.gendis.2025.101913_bib1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.annonc.2021.08.2153","article-title":"Therapeutic cancer vaccines revamping: technology advancements and pitfalls","volume":"32","author":"Antonarelli","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution","volume":"137","author":"Steinman","year":"1973","journal-title":"J Exp Med"},{"key":"10.1016\/j.gendis.2025.101913_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcdb.2017.12.009","article-title":"Dendritic cell subsets","volume":"84","author":"Macri","year":"2018","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"Plasmacytoid dendritic cells: development, regulation, and function","volume":"50","author":"Reizis","year":"2019","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.gendis.2025.101913_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"6673","key":"10.1016\/j.gendis.2025.101913_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2025.101913_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of T(H) cells: a balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.gendis.2025.101913_bib8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0960-9822(95)00175-8","article-title":"T-cell activation: two for T","volume":"5","author":"Guerder","year":"1995","journal-title":"Curr Biol"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/imm.13114","article-title":"Cancer immune escape: MHC expression in primary tumours versus metastases","volume":"158","author":"Garrido","year":"2019","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib10","first-page":"450","article-title":"Recent advances in antitumor dendritic cell vaccines","volume":"38","author":"Ge","year":"2023","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.gendis.2025.101913_bib12","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s00262-018-2157-5","article-title":"Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer","volume":"67","author":"Rojas-Sep\u00falveda","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"issue":"23","key":"10.1016\/j.gendis.2025.101913_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2100588118","article-title":"Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer","volume":"118","author":"Wei","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gendis.2025.101913_bib16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.98579.3","article-title":"Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination","volume":"13","author":"Tang","year":"2024","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/vaccines7030120","article-title":"In vivo administration of recombinant human granulocyte colony-stimulating factor increases the immune effectiveness of dendritic cell-based cancer vaccination","volume":"7","author":"Shimodaira","year":"2019","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib18","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s00262-023-03400-y","article-title":"A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma","volume":"72","author":"Dasyam","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gendis.2025.101913_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.960317","article-title":"Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action","volume":"12","author":"Tilsed","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.2174\/1871520615666150907094139","article-title":"Combination of DC vaccine and conventional chemotherapeutics","volume":"16","author":"Dong","year":"2016","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100334","article-title":"Safety and efficacy of dendritic cell-based immunotherapy (DCVAC\/LuCa) combined with carboplatin\/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers","volume":"7","author":"Zhong","year":"2022","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.gendis.2025.101913_bib22","first-page":"1270","article-title":"Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients","volume":"18","author":"Eisendle","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gendis.2025.101913_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1368103","article-title":"Dendritic cell vaccination combined with carboplatin\/paclitaxel for metastatic endometrial cancer patients: results of a phase I\/II trial","volume":"15","author":"Koeneman","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13311-018-0650-3","article-title":"A dendritic cell-targeted adenoviral vector facilitates adaptive immune response against human glioma antigen (CMV-IE) and prolongs survival in a human glioma tumor model","volume":"15","author":"Kim","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.gendis.2025.101913_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215031","article-title":"Delivery of self-amplifying RNA vaccines in in vitro reconstituted virus-like particles","volume":"14","author":"Biddlecome","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jconrel.2011.11.034","article-title":"Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets","volume":"160","author":"Markov","year":"2012","journal-title":"J Contr Release"},{"key":"10.1016\/j.gendis.2025.101913_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.biomaterials.2018.12.019","article-title":"Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation","volume":"195","author":"Coolen","year":"2019","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.gendis.2025.101913_bib30","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","author":"Wilgenhof","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.gendis.2025.101913_bib31","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","article-title":"A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases","volume":"69","author":"Jansen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"10.1016\/j.gendis.2025.101913_bib32","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1021\/acs.accounts.1c00550","article-title":"Lipid nanoparticle-mRNA formulations for therapeutic applications","volume":"54","author":"Wang","year":"2021","journal-title":"Acc Chem Res"},{"issue":"19","key":"10.1016\/j.gendis.2025.101913_bib33","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/polym14194195","article-title":"Design strategies for and stability of mRNA-lipid nanoparticle COVID-19 vaccines","volume":"14","author":"Liu","year":"2022","journal-title":"Polymers"},{"issue":"10","key":"10.1016\/j.gendis.2025.101913_bib34","first-page":"2091","article-title":"Dendritic cells based immunotherapy","volume":"7","author":"Shang","year":"2017","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-023-01457-x","article-title":"Clinical development of mRNA therapies against solid tumors","volume":"16","author":"Wu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nm0597-558","article-title":"Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells","volume":"3","author":"Gong","year":"1997","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.gendis.2025.101913_bib37","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2017-11-785873","article-title":"Vaccine therapy in hematologic malignancies","volume":"131","author":"Avigan","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clim.2004.08.004","article-title":"Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation","volume":"113","author":"Koido","year":"2004","journal-title":"Clin Immunol"},{"issue":"23","key":"10.1016\/j.gendis.2025.101913_bib39","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1158\/1078-0432.CCR-23-0235","article-title":"Randomized phase II trial of dendritic cell\/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401","volume":"29","author":"Chung","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1148\/radiol.2020192190","article-title":"High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy","volume":"295","author":"Geboers","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.gendis.2025.101913_bib41","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1038\/srep03382","article-title":"Cell electrofusion using nanosecond electric pulses","volume":"3","author":"Rems","year":"2013","journal-title":"Sci Rep"},{"issue":"18","key":"10.1016\/j.gendis.2025.101913_bib42","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/elps.201100082","article-title":"A high-throughput dielectrophoresis-based cell electrofusion microfluidic device","volume":"32","author":"Hu","year":"2011","journal-title":"Electrophoresis"},{"key":"10.1016\/j.gendis.2025.101913_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bioelechem.2019.02.007","article-title":"Electrofusion by a bipolar pulsed electric field: increased cell fusion efficiency for monoclonal antibody production","volume":"127","author":"Ke","year":"2019","journal-title":"Bioelectrochemistry"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib44","doi-asserted-by":"crossref","DOI":"10.1063\/5.0205100","article-title":"Mechanism study on the influences of buffer osmotic pressure on microfluidic chip-based cell electrofusion","volume":"8","author":"Xu","year":"2024","journal-title":"APL Bioeng"},{"issue":"5\u20136","key":"10.1016\/j.gendis.2025.101913_bib45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00232-024-00320-5","article-title":"Feasibility study for the use of gene electrotransfer and cell electrofusion as a single-step technique for the generation of activated cancer cell vaccines","volume":"257","author":"U\u0161aj","year":"2024","journal-title":"J Membr Biol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101913_bib46","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/v13101973","article-title":"Cell fusion and syncytium formation in betaherpesvirus infection","volume":"13","author":"Tang","year":"2021","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.gendis.2025.101913_bib47","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm923","article-title":"A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines","volume":"9","author":"Phan","year":"2003","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib48","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.4049\/jimmunol.173.7.4297","article-title":"Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides","volume":"173","author":"Hiraoka","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib49","first-page":"249","article-title":"Anti-tumor effects of fusion cells of type 1 dendritic cells and Meth A tumor cells using hemagglutinating virus of Japan-envelope","volume":"35","author":"Yanai","year":"2009","journal-title":"Int J Oncol"},{"issue":"22","key":"10.1016\/j.gendis.2025.101913_bib50","first-page":"6566","article-title":"Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells","volume":"62","author":"Bateman","year":"2002","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.gendis.2025.101913_bib51","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10616-020-00416-5","article-title":"Production of interspecies somatic\/pluripotent heterokaryons using polyethylene glycol (PEG) and selection by imaging flow cytometry for the study of nuclear reprogramming","volume":"72","author":"Villafranca","year":"2020","journal-title":"Cytotechnology"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib52","first-page":"347","article-title":"Characterization of structure and direct antigen presentation by dendritic\/tumor-fused cells as cancer vaccines","volume":"33","author":"Koido","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gendis.2025.101913_bib53","article-title":"Development of a dendritic cell\/tumor cell fusion cell membrane nano-vaccine for the treatment of ovarian cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib54","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.vaccine.2019.01.004","article-title":"Novel fusion cells derived from tumor cells expressing the heterologous \u03b1-galactose epitope and dendritic cells effectively target cancer","volume":"37","author":"Mo","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.gendis.2025.101913_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1361094","article-title":"Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells","volume":"6","author":"He","year":"2017","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41419-023-05914-w","article-title":"A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib57","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<618::AID-IJC4>3.0.CO;2-Z","article-title":"Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma","volume":"85","author":"Trefzer","year":"2000","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib58","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma","volume":"117","author":"Rosenblatt","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib59","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/CJI.0b013e3180de4ce8","article-title":"Phase I\/II study of vaccination with electrofused allogeneic dendritic cells\/autologous tumor-derived cells in patients with stage IV renal cell carcinoma","volume":"30","author":"Avigan","year":"2007","journal-title":"J Immunother"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202149548","article-title":"Classical DC2 subsets and monocyte-derived DC: delineating the developmental and functional relationship","volume":"53","author":"Backer","year":"2023","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.gendis.2025.101913_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113133","article-title":"Feasibility of using monocyte-derived dendritic cells obtained from cryopreserved cells for DC-based vaccines","volume":"498","author":"Usero","year":"2021","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib62","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1038\/s41598-018-23943-w","article-title":"Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy","volume":"8","author":"Shinde","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.gendis.2025.101913_bib63","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","article-title":"Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells","volume":"22","author":"Schreibelt","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.gendis.2025.101913_bib64","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic cell\u2013based immunotherapy: state of the art and beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-019-0580-6","article-title":"The clinical application of cancer immunotherapy based on naturally circulating dendritic cells","volume":"7","author":"Bol","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib66","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/pcmr.12618","article-title":"The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients","volume":"31","author":"Charles","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.gendis.2025.101913_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.749190","article-title":"The role of plasmacytoid dendritic cells in cancers","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"58","key":"10.1016\/j.gendis.2025.101913_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc7302","article-title":"Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells","volume":"6","author":"Yun","year":"2021","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib70","doi-asserted-by":"crossref","first-page":"11708","DOI":"10.18632\/oncotarget.14315","article-title":"TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00262-022-03271-9","article-title":"Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinoma","volume":"72","author":"Laheurte","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.gendis.2025.101913_bib72","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.4049\/jimmunol.2300290","article-title":"Integrin \u03b1v\u03b23 limits cytokine production by plasmacytoid dendritic cells and restricts TLR-driven autoimmunity","volume":"212","author":"Lorant","year":"2024","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib73","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","article-title":"Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients","volume":"73","author":"Tel","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1738812","article-title":"An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial","volume":"9","author":"Charles","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib75","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s40425-019-0787-6","article-title":"Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer","volume":"7","author":"Westdorp","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib76","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/cells11020222","article-title":"Plasmacytoid dendritic cells and cancer immunotherapy","volume":"11","author":"Fu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.gendis.2025.101913_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113250","article-title":"Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine","volume":"152","author":"Xia","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","article-title":"Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication","volume":"21","author":"Mathieu","year":"2019","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101913_bib79","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","article-title":"Visualizing synaptic transfer of tumor antigens among dendritic cells","volume":"37","author":"Ruhland","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gendis.2025.101913_bib80","series-title":"Dendritic Cell Extracellular Vesicles. Immunobiology of Dendritic Cells Part B","first-page":"213","author":"Kowal","year":"2019"},{"issue":"8","key":"10.1016\/j.gendis.2025.101913_bib81","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3390\/pharmaceutics15082070","article-title":"Dendritic cell-derived exosomes in cancer immunotherapy","volume":"15","author":"Luo","year":"2023","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib82","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/intimm\/dxf048","article-title":"Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells","volume":"14","author":"Vincent-Schneider","year":"2002","journal-title":"Int Immunol"},{"issue":"7340","key":"10.1016\/j.gendis.2025.101913_bib83","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature09863","article-title":"Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection","volume":"471","author":"Wakim","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.gendis.2025.101913_bib84","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/ni854","article-title":"Indirect activation of na\u00efve CD4+ T cells by dendritic cell-derived exosomes","volume":"3","author":"Th\u00e9ry","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.gendis.2025.101913_bib85","first-page":"692","article-title":"Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets","volume":"5","author":"Romagnoli","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.gendis.2025.101913_bib86","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jconrel.2022.11.053","article-title":"Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies","volume":"353","author":"Li","year":"2023","journal-title":"J Contr Release"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib87","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1479-5876-3-9","article-title":"A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer","volume":"3","author":"Morse","year":"2005","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-3-10","article-title":"Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial","volume":"3","author":"Escudier","year":"2005","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib89","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1071008","article-title":"Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC","volume":"5","author":"Besse","year":"2016","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bcmd.2005.05.003","article-title":"Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses","volume":"35","author":"Segura","year":"2005","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib91","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CJI.0b013e3181fe535b","article-title":"Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-\u03b3","volume":"34","author":"Viaud","year":"2011","journal-title":"J Immunother"},{"issue":"25","key":"10.1016\/j.gendis.2025.101913_bib92","doi-asserted-by":"crossref","first-page":"38707","DOI":"10.18632\/oncotarget.9585","article-title":"Exosomal cancer immunotherapy is independent of MHC molecules on exosomes","volume":"7","author":"Hiltbrunner","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.gendis.2025.101913_bib93","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.3390\/cancers13153667","article-title":"DC-derived exosomes for cancer immunotherapy","volume":"13","author":"Yao","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib94","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s40425-019-0716-8","article-title":"Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy","volume":"7","author":"Calmeiro","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib95","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.3390\/ijms24044253","article-title":"Dendritic cell and cancer therapy","volume":"24","author":"Galati","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib96","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/vaccines8040706","article-title":"DC-based vaccines for cancer immunotherapy","volume":"8","author":"Fu","year":"2020","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib97","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"16","key":"10.1016\/j.gendis.2025.101913_bib98","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41388-020-1216-5","article-title":"The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment","volume":"39","author":"Brown","year":"2020","journal-title":"Oncogene"},{"issue":"95","key":"10.1016\/j.gendis.2025.101913_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi4191","article-title":"A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression","volume":"9","author":"Plebanek","year":"2024","journal-title":"Sci Immunol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib101","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.semcancer.2012.02.010","article-title":"Tumor associated regulatory dendritic cells","volume":"22","author":"Ma","year":"2012","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10.1016\/j.gendis.2025.101913_bib102","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.4049\/jimmunol.181.8.5194","article-title":"Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells","volume":"181","author":"Belladonna","year":"2008","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib103","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"issue":"34","key":"10.1016\/j.gendis.2025.101913_bib104","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1038\/s41388-021-01946-8","article-title":"DCision-making in tumors governs T cell anti-tumor immunity","volume":"40","author":"Alfei","year":"2021","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib105","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"10.1016\/j.gendis.2025.101913_bib106","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-19-1321","article-title":"Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response","volume":"26","author":"Garris","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gendis.2025.101913_bib108","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3389\/fimmu.2018.03176","article-title":"Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy","volume":"9","author":"Patente","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.gendis.2025.101913_bib109","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1080\/08820139.2022.2109486","article-title":"Dendritic cell-based vaccines against cancer: challenges, advances and future opportunities","volume":"51","author":"Fu","year":"2022","journal-title":"Immunol Investig"},{"issue":"7822","key":"10.1016\/j.gendis.2025.101913_bib110","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2025.101913_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105374","article-title":"Dendritic cell vaccine therapy for colorectal cancer","volume":"164","author":"Wooster","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.gendis.2025.101913_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117580","article-title":"Dendritic cell therapy in cancer treatment; the state-of-the-art","volume":"254","author":"Sadeghzadeh","year":"2020","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.gendis.2025.101913_bib113","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","article-title":"Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint blockade","volume":"10","author":"Budimir","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.gendis.2025.101913_bib114","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101913_bib115","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gendis.2025.101913_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114954","article-title":"Advances in dendritic cell vaccination therapy of cancer","volume":"164","author":"Najafi","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"670","key":"10.1016\/j.gendis.2025.101913_bib117","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo3605","article-title":"Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment","volume":"14","author":"Kirchhammer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.gendis.2025.101913_bib118","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol"},{"issue":"8","key":"10.1016\/j.gendis.2025.101913_bib119","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.ymthe.2020.05.018","article-title":"Lentiviral-vector-based dendritic cell vaccine synergizes with checkpoint blockade to clear chronic viral infection","volume":"28","author":"Norton","year":"2020","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.gendis.2025.101913_bib121","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007661","article-title":"Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade","volume":"11","author":"Luo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.gendis.2025.101913_bib122","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/vaccines12070777","article-title":"Therapeutic anti-tumor efficacy of DC-based vaccines targeting TME-associated antigens is improved when combined with a chemokine-modulating regimen and\/or anti-PD-L1","volume":"12","author":"Taylor","year":"2024","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib123","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib124","article-title":"Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells","volume":"5","author":"Sprooten","year":"2024","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1697","article-title":"Nanobody: a versatile tool for cancer diagnosis and therapeutics","volume":"13","author":"Liu","year":"2021","journal-title":"WIREs Nanomed Nanobiotechnol"},{"issue":"25","key":"10.1016\/j.gendis.2025.101913_bib126","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.7150\/thno.34941","article-title":"Theranostics in immuno-oncology using nanobody derivatives","volume":"9","author":"Lecocq","year":"2019","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.gendis.2025.101913_bib127","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal Bioanal Chem"},{"issue":"10","key":"10.1016\/j.gendis.2025.101913_bib128","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1039\/D0CS00718H","article-title":"Engineering nanomedicine for glutathione depletion-augmented cancer therapy","volume":"50","author":"Xiong","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.gendis.2025.101913_bib129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2021.09.028","article-title":"A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine","volume":"522","author":"Shi","year":"2021","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1295903","article-title":"Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma","volume":"6","author":"Garg","year":"2017","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.gendis.2025.101913_bib131","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.gendis.2025.101913_bib132","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.gendis.2025.101913_bib133","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib134","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"10.1016\/j.gendis.2025.101913_bib135","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.gendis.2025.101913_bib136","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcyt.2019.03.313","article-title":"CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia","volume":"21","author":"Wu","year":"2019","journal-title":"Cytotherapy"},{"issue":"11","key":"10.1016\/j.gendis.2025.101913_bib137","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.gendis.2025.101913_bib138","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2017.02.010","article-title":"The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells","volume":"45","author":"Ramachandran","year":"2017","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib139","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40259-019-00354-5","article-title":"Immunogenicity of chimeric antigen receptor T-cell therapeutics","volume":"33","author":"Gorovits","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.gendis.2025.101913_bib140","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/IJN.S297631","article-title":"Nanobody: a small antibody with big implications for tumor therapeutic strategy","volume":"16","author":"Sun","year":"2021","journal-title":"Int J Nanomed"},{"issue":"10","key":"10.1016\/j.gendis.2025.101913_bib141","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.gendis.2025.101913_bib142","first-page":"5263","article-title":"Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies","volume":"11","author":"Chen","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.gendis.2025.101913_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111328","article-title":"Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-\u03b1-specific nanobody","volume":"137","author":"Nie","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.gendis.2025.101913_bib144","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/iub.2019","article-title":"T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy","volume":"71","author":"Hajari Taheri","year":"2019","journal-title":"IUBMB Life"},{"issue":"16","key":"10.1016\/j.gendis.2025.101913_bib145","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.gendis.2025.101913_bib146","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.7150\/thno.84946","article-title":"A dendritic\/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor","volume":"13","author":"Sun","year":"2023","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.gendis.2025.101913_bib147","article-title":"Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine","volume":"4","author":"Dan","year":"2023","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.gendis.2025.101913_bib148","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.4049\/jimmunol.1001294","article-title":"Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment","volume":"185","author":"Qu","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101913_bib149","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.989764","article-title":"Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication","volume":"4","author":"Draghiciu","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2 Pt 2","key":"10.1016\/j.gendis.2025.101913_bib150","first-page":"E99","article-title":"Sipuleucel-T (Provenge\u00ae) for castration-resistant prostate cancer","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.gendis.2025.101913_bib151","article-title":"Novel strategy for manufacturing autologous dendritic cell\/allogeneic tumor lysate vaccines for glioblastoma","volume":"2","author":"Parney","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"Suppl","key":"10.1016\/j.gendis.2025.101913_bib152","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1080\/13547500500216629","article-title":"Biomarkers and assessment of vaccine responses","volume":"10","author":"Hogrefe","year":"2005","journal-title":"Biomarkers"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:30:00Z","timestamp":1777303800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225004027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2352304225004027"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101913","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dendritic cell vaccines: Current research progress, challenges, and opportunities","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101913"}}